Optimization of vitamin K antagonist treatment: Near patient monitoring versus standard of care a parallel group clinical trial in older patients with atrial fibrillation.

Purpose: Atrial fibrillation (AF) is common in the elderly population and is associated with a high risk of thromboembolic events. Although non-vitamin K oral anticoagulants (NOACs) are the preferred drugs in antithrombotic therapy for AF, Vitamin K Anticoagulant drug (VKA) treatment is still used i...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Clinical Pharmacology Vol. 81; no. 9; pp. 1365 - 1372
Autores principales: van Elp, Margriet, Beinema, Maarten, Brouwers, Jacobus R. B. J., van 't Riet, Esther, van de Leur, Sjef, Schreiber, Ildiko, Jansman, Frank G. A.
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: Springer Nature Sep2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=187672826&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 187672826
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Sep2025
      vid: 81
      iid: 9
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        187672826
        186560535
        187672826
        187672826
        10.1007/s00228-025-03878-8
        187672826
      ppf: 1365
      ppct: 7
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Optimization of vitamin K antagonist treatment: Near patient monitoring versus standard of care a parallel group clinical trial in older patients with atrial fibrillation.
      aug:
        au:
          van Elp, Margriet
          Beinema, Maarten
          Brouwers, Jacobus R. B. J.
          van 't Riet, Esther
          van de Leur, Sjef
          Schreiber, Ildiko
          Jansman, Frank G. A.
        affil: https://ror.org/05w8df681 Department of Clinical Pharmacy, Deventer Hospital, Nico Bolkesteinlaan 75, 7416 SE, Deventer, The Netherlands
      sug:
        subj:
          Atrial Fibrillation Drug Therapy
          Vitamin K Antagonists and Inhibitors
          Anticoagulants Therapeutic Use
          Drug Monitoring
          Quality of Health Care
          Patient Safety
          Home Health Care
          Clinical Information Systems
          Netherlands
          Funding Source
          Human
          Male
          Female
          Aged
          Aged, 80 and Over
          Randomized Controlled Trials
          Random Assignment
          Prospective Studies
          Cardiac Patients
          Frail Elderly
          Benzopyrans
          Anticoagulants Adverse Effects
          Hemorrhage Chemically Induced
          Dosage Calculation
          International Normalized Ratio
          Unpaired T-Tests
          Chi Square Test
          Odds Ratio
          Confidence Intervals
          Data Analysis Software
          Descriptive Statistics
          Aged: 65+ years
          Aged, 80 & over
          Male
          Female
      ab: Purpose: Atrial fibrillation (AF) is common in the elderly population and is associated with a high risk of thromboembolic events. Although non-vitamin K oral anticoagulants (NOACs) are the preferred drugs in antithrombotic therapy for AF, Vitamin K Anticoagulant drug (VKA) treatment is still used in a considerable proportion of patients with AF. Moreover, recent findings revealed that switching VKA to NOAC is associated with more bleeding complications in frail older patients with AF. Standard of care (SOC) monitoring of VKA treatment consists of venous blood sampling and back office dosage advice with a chain of processes and involvement of several health care professionals. We have designed a new procedure for monitoring (Near Patient Therapeutic Monitoring / NPTM) in order to improve the quality and safety of VKA treatment. NPTM consists of INR measurement with a point-of-care (POC) device in the home setting of a patient, performed by one professional and with an instant dosage advice. Methods: This is a cluster-randomised, parallel group, open label study to compare SOC with NPTM of VKA treatment in patients in a home setting. The follow-up period was one year. The primary outcome was time in therapeutic range (TTR), and secondary outcomes were adverse events (deaths, bleeding and thromboembolic events). Results: 555 Patients were included in the study. After randomisation, 271 patients received SOC and 284 patients received NPTM. The TTR did not differ significantly: 63.71% versus 62.47% (p > 0.05) for SOC and NPTM, respectively. Significant differences were found for all-cause death (SOC n = 34 versus NPTM n = 16, p < 0.05, OR 0.47, 95% CI: 0.25–0.87), total number of minor bleedings (79 events in SOC vs 52 in NPTM, p < 0.05, OR 64 (95%CI: 0,37–0,81) and all non-major bleedings (100 events in SOC vs 67 in NPTM, p < 0.05, OR 0.62 (95% CI: 043–0.90). Conclusions: NPTM of VKA treatment in AF-patients does not result in an improved TTR when compared to SOC. All-cause death, total number of minor bleedings and all non-major bleedings may be reduced in NPTM, although the study was not powered for these secondary outcomes. Future studies are needed to determine the cost-effectiveness of NTPM versus SOC.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N